Berries Health Lipid Panel Testing

Our mission is to prevent heart disease byidentifying genetic causes, personalizingtreatments, and empowering families to takecontrol of their health for future generations.

Did you know that familial

hypercholesterolemia (FH) occurs in about 1 in 250 people, while elevated lipoprotein(a)[Lp(a)] levels can be found in approximately 1 in 5 individuals. Those who carry these genetic conditions can face a risk of heart attacks and strokes that are up to 22 times higher.

Why Consider Berries Health Genetic Testing?

• The Berries Lipid Panel is designed to detect and address the following:
• Detect monogenic and polygenic variants associated with hyperlipidemia and atherosclerosis.
• Calculate the risk of coronary heart disease and associated mortality.
• Assess response to statins and identify potential adverse effects.
• Provide genetic evidence to guide the selection of PCSK9 inhibitors.
• Rule out pathogenic variants in the PCSK9gene and evaluate their impact on lipid-lowering.
• Evaluate responses to other potential lipid-lowering medications based on individual genotype.

What are the Benefits of Berries Lipid Panel Testing?

• Confirm FH diagnosis with genetic testing.
• Identify higher risk with a positive genetic test result.
• Improve treatment options with personalized, data-driven insights.
• Enhance family screening to support better health management.
• Address genetic factors to significantly improve heart disease prevention and management of unaffected families.
• Receive free genetic consultation with a board-certified geneticist.
• Benefit from wellness coaching by an expert certified health coach.

More to Lipid Panel Testing

Berries Lipid Panel Testing also detects the following genetic and health abnormalities.

1) Familial (inherited) Hyperlipidemia

2) Hyperlipoproteinemia: including hyperchylomicronemia, lipoprotein metabolism disorder including Lipoprotein A (LPa). APOA, APOB, APOC, APOE

3) Coronary Artery Disease/Atherosclerosis Risk Assessment Score.

4) Hyperlipidemia, Hyperlipoproteinemia, and Atherosclerosis Risk Susceptibility SNPs:

5) Lipid-lowering medication efficacy and adverse event evaluation:

Statins: Atorvastatin (Lipitor), Fluvastatin (Lescol), Lovastatin (Altoprev), Pitavastatin (Livalo), and Rosuvastatin (Crestor).

Ezetimibe (Zetia)

Gemfibrozil (Lopid) and fenofibrate (Tricor)

PCSK9 inhibitors (e.g., alirocumab, evolocumab)

6) Genetic consultation and wellness management.

Limitations of Testing 

This test is designed to identify germline pathogenic variants, including single nucleotide polymorphisms (SNPs) and small insertions and deletions (indels) of up to 1 kilobase pair (kbp). It also analyzes mutations within coding regions and the exon-intron boundaries, specifically within 50 base pairs. Any deletions or duplications larger than 1 kbp that are reportable will be confirmed using orthogonal methods before being included in the final report.